Cargando…

Clinical risk factors for late intestinal toxicity after radiotherapy: a systematic review protocol

BACKGROUND: Late intestinal toxicity after radiotherapy (LITAR) not only limits the radiation dose, which subsequently leads to unfavorable clinical outcomes, but also significantly lowers the quality of life in an increasing number of cancer survivors. Therefore, identifying clinical risk factors f...

Descripción completa

Detalles Bibliográficos
Autores principales: Qin, Qiyuan, Huang, Qingshan, Zhong, Qinghua, Fan, Xinjuan, Chen, Dianke, Wang, Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3680145/
https://www.ncbi.nlm.nih.gov/pubmed/23759030
http://dx.doi.org/10.1186/2046-4053-2-39
_version_ 1782273076470218752
author Qin, Qiyuan
Huang, Qingshan
Zhong, Qinghua
Fan, Xinjuan
Chen, Dianke
Wang, Lei
author_facet Qin, Qiyuan
Huang, Qingshan
Zhong, Qinghua
Fan, Xinjuan
Chen, Dianke
Wang, Lei
author_sort Qin, Qiyuan
collection PubMed
description BACKGROUND: Late intestinal toxicity after radiotherapy (LITAR) not only limits the radiation dose, which subsequently leads to unfavorable clinical outcomes, but also significantly lowers the quality of life in an increasing number of cancer survivors. Therefore, identifying clinical risk factors for LITAR is important for establishing a predictive model in the clinical setting of decision-making for these patients. This review aims to systematically summarize and clarify the clinical factors that can be potentially associated with an increased risk of moderate/severe LITAR in patients with abdominal or pelvic malignancies. METHODS/DESIGN: MEDLINE, EMBASE, Web of Science, Cochrane Central Register of Controlled Trials, Scopus, Google Scholar and Chinese BioMed will be systematically searched to identify appropriate studies. Citations of the retrieved studies and recent reviews will also be searched separately by case. The enrolled studies should at least have the following information: (1) a clear definition and information on the LITAR severity; (2) assess clinical factors for moderate/severe toxicity with adjusted risk estimates; (3) have a cohort, case–control, randomized controlled trial and controlled clinical trial study design. Two authors will independently review the abstract and full text of retrieved studies, extract data from eligible studies and assess the risk of bias. Disagreements will be discussed among reviewers until a consensus is reached. The effect of identified risk factors will be displayed in forest plots. If the information is sufficient, results will be synthesized by a meta-analysis with the random effects model to pool the estimate of risk posed by clinical factors. Subgroup and sensitivity analysis will be used to explore the sources of heterogeneity. DISCUSSION: This review will summarize the evidence of clinical risk factors for moderate/severe LITAR. The results may help guide decision-making and minimize the side effects of therapeutic modalities in the clinical setting. TRIAL REGISTRATION: This review has been registered at PROSPERO. The registration no. is CRD42013003744.
format Online
Article
Text
id pubmed-3680145
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-36801452013-06-13 Clinical risk factors for late intestinal toxicity after radiotherapy: a systematic review protocol Qin, Qiyuan Huang, Qingshan Zhong, Qinghua Fan, Xinjuan Chen, Dianke Wang, Lei Syst Rev Protocol BACKGROUND: Late intestinal toxicity after radiotherapy (LITAR) not only limits the radiation dose, which subsequently leads to unfavorable clinical outcomes, but also significantly lowers the quality of life in an increasing number of cancer survivors. Therefore, identifying clinical risk factors for LITAR is important for establishing a predictive model in the clinical setting of decision-making for these patients. This review aims to systematically summarize and clarify the clinical factors that can be potentially associated with an increased risk of moderate/severe LITAR in patients with abdominal or pelvic malignancies. METHODS/DESIGN: MEDLINE, EMBASE, Web of Science, Cochrane Central Register of Controlled Trials, Scopus, Google Scholar and Chinese BioMed will be systematically searched to identify appropriate studies. Citations of the retrieved studies and recent reviews will also be searched separately by case. The enrolled studies should at least have the following information: (1) a clear definition and information on the LITAR severity; (2) assess clinical factors for moderate/severe toxicity with adjusted risk estimates; (3) have a cohort, case–control, randomized controlled trial and controlled clinical trial study design. Two authors will independently review the abstract and full text of retrieved studies, extract data from eligible studies and assess the risk of bias. Disagreements will be discussed among reviewers until a consensus is reached. The effect of identified risk factors will be displayed in forest plots. If the information is sufficient, results will be synthesized by a meta-analysis with the random effects model to pool the estimate of risk posed by clinical factors. Subgroup and sensitivity analysis will be used to explore the sources of heterogeneity. DISCUSSION: This review will summarize the evidence of clinical risk factors for moderate/severe LITAR. The results may help guide decision-making and minimize the side effects of therapeutic modalities in the clinical setting. TRIAL REGISTRATION: This review has been registered at PROSPERO. The registration no. is CRD42013003744. BioMed Central 2013-06-07 /pmc/articles/PMC3680145/ /pubmed/23759030 http://dx.doi.org/10.1186/2046-4053-2-39 Text en Copyright © 2013 Qin et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Protocol
Qin, Qiyuan
Huang, Qingshan
Zhong, Qinghua
Fan, Xinjuan
Chen, Dianke
Wang, Lei
Clinical risk factors for late intestinal toxicity after radiotherapy: a systematic review protocol
title Clinical risk factors for late intestinal toxicity after radiotherapy: a systematic review protocol
title_full Clinical risk factors for late intestinal toxicity after radiotherapy: a systematic review protocol
title_fullStr Clinical risk factors for late intestinal toxicity after radiotherapy: a systematic review protocol
title_full_unstemmed Clinical risk factors for late intestinal toxicity after radiotherapy: a systematic review protocol
title_short Clinical risk factors for late intestinal toxicity after radiotherapy: a systematic review protocol
title_sort clinical risk factors for late intestinal toxicity after radiotherapy: a systematic review protocol
topic Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3680145/
https://www.ncbi.nlm.nih.gov/pubmed/23759030
http://dx.doi.org/10.1186/2046-4053-2-39
work_keys_str_mv AT qinqiyuan clinicalriskfactorsforlateintestinaltoxicityafterradiotherapyasystematicreviewprotocol
AT huangqingshan clinicalriskfactorsforlateintestinaltoxicityafterradiotherapyasystematicreviewprotocol
AT zhongqinghua clinicalriskfactorsforlateintestinaltoxicityafterradiotherapyasystematicreviewprotocol
AT fanxinjuan clinicalriskfactorsforlateintestinaltoxicityafterradiotherapyasystematicreviewprotocol
AT chendianke clinicalriskfactorsforlateintestinaltoxicityafterradiotherapyasystematicreviewprotocol
AT wanglei clinicalriskfactorsforlateintestinaltoxicityafterradiotherapyasystematicreviewprotocol